Abilita Bio Appoints Christopher B. Roth, PhD to Vice President, Innovation
– Dr. Roth will guide the development of novel protein engineering and drug discovery technologies that strengthen our core platform –
SAN DIEGO, Calif. April 12, 2016 –Abilita Bio, Inc. announced today that Christopher B. Roth has been appointed to the role of Vice President, Innovation. In conjunction with this appointment, Dr. Roth will step down as a member of Abilita Bio’s Scientific Advisory Board, which he joined in 2015.
Dr. Roth brings more than ten years of innovation in membrane protein engineering, structural biology and drug discovery to Abilita Bio. He most recently served as a Research Scientist at Receptos, Inc. from 2009 to 2015, where he was a founding member of the scientific team and the lead inventor of critical GPCR protein engineering technologies that were patented and licensed to domestic and international industry partners. Prior to joining Receptos, Dr. Roth conducted postdoctoral research in GPCR structural biology in the laboratory of Dr. Raymond Stevens at The Scripps Research Institute, where he also earned his PhD. Dr. Roth earned his B.S. in Molecular and Cellular Biology from the University of California at Santa Barbara.
G Protein-Coupled Receptors (GPCRs) represent the largest class of membrane proteins in humans, and bind almost all of the known neurotransmitters and hormones that are released synaptically or secreted into the circulatory system. GPCRs are expressed in all tissue types and organs, and are associated with many diseases. The GPCR super-family includes around 400 medically relevant targets. To date more than 110 receptors have been exploited as drug targets, while most of the remaining receptors are orphan (130) or under-characterized.
About Abilita Bio, Inc.
Abilita Bio, Inc. was founded in June 2014 and is an innovation-driven biotechnology company focused on enabling discovery and development of drugs targeting challenging membrane proteins, including G Protein-Coupled Receptors (GPCRs) through the application of our Enabled Membrane Proteins (EMPs™) technology platform. Abilita Bio is privately held and owns all the rights to the EMP™ technology and has established several global collaborations around the EMP™ platform, including a multi-target proof of concept agreement with an undisclosed global Pharmaceutical Company.
Abilita Bio, Inc.
Mauro Mileni, PhD
President & CEO